Geneva: Research on the use of dexamethasone for Covid-19 is still in the early stages, the World Health Organization said, urging the public to be cautious.
While the results from the University of Oxford were “very significant,” scientists still need to see the full data from the trial, Mike Ryan, executive director of the WHO’s emergencies program, said during a press conference.
Earlier this week, scientists at Oxford said results from a trial showed the steroid reduced death rates by around a third among the most severely ill hospitalized Covid-19 patients.
Besides dexamethasone’s approval in the U.K., there are currently no other approved treatments for the virus, which has infected more than 8.1 million people worldwide.
